Vitamin D 3 supplementation among adult patients with cystic fibrosis

• Published in: Clinical nutrition (Edinburgh, Scotland) Scotland), 2017-12, Vol.36 (6), p.1580
• Main Authors: Coriati, Adèle, Labrèche, Évelyne, Mailhot, Marjolaine, Mircescu, Hortensia, Berthiaume, Yves, Lavoie, Annick, Rabasa-Lhoret, Rémi
• Format: Article
• Language: English
• Subjects: Adult; Body Mass Index; Cholecalciferol - administration & dosage; Cholecalciferol - blood; Cystic Fibrosis - blood; Cystic Fibrosis - complications; Cystic Fibrosis - drug therapy; Dietary Supplements; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Retrospective Studies; Seasons; Vitamin D Deficiency - blood; Vitamin D Deficiency - drug therapy; Vitamin D Deficiency - etiology; Young Adult
• ISSN: 1532-1983
• DOI: 10.1016/j.clnu.2016.10.002

Vitamin D (Vit D) deficiency in cystic fibrosis (CF) is partially secondary to exocrine pancreatic insufficiency. Our aim was to establish a Vit D supplementation protocol that will increase 25(OH)D to the recommended level (30 ng/mL). Retrospective study of 200 patients (≥18 years) conducted from February 2007 to June 2014 at the CF clinic of the Centre Hospitalier de l'Université de Montréal. Vit D supplementation protocol was 1600 IU/day or 10,000 IU/week during the summer (May 1st to October 31st) and 3200 IU/day or 20,000 IU/week during the winter (November 1st to April 30th), in addition to the 1200 IU/day included in multivitamins. Significant increase in serum 25(OH)D levels from baseline (25.9 ± 10.3 ng/mL) to follow-up (37.0 ± 11.4 ng/mL) (P ≤ 0.001). At follow-up, increased doses during the winter improved serum 25(OH)D levels to a degree comparable to the summer. This supplementation protocol is efficient and needs to be tested in other CF adult cohorts and correlated to potential health benefit measurements.